Trials Today

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Purpose

The main objective of this study is to assess pharmacokinetics, safety, and tolerability of ABBV-932 in healthy adult participants.

Conditions

Generalized Anxiety Disorder (GAD)
Healthy Participants

Eligibility

Eligible Ages: Between 18 Years and 65 Years
Eligible Genders: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

Parts 1 and 2: Healthy individuals with body-mass index (BMI) >= 18.0 to <= 32.0 kg/m2, rounded to the tenths decimal. - Part 3: Healthy Japanese, Han Chinese individuals with BMI >= 18.0 to <= 30.0 kg/m2, rounded to the tenths decimal. - Condition of general good health based upon the results of a medical history, physical examination, vital signs, laboratory profile, neurological examination, and a 12-lead ECG.

Exclusion Criteria

History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study drug.

Study Design

Phase: Phase 1
Study Type: Interventional
Allocation: Randomized
Intervention Model: Sequential Assignment
Primary Purpose: Treatment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

Arm	Description	Assigned Intervention
Experimental Part 1: ABBV-932	Participants will receive ABBV-932 on Day 1 and followed for 30 days.	Drug: ABBV-932 Oral Capsule
Placebo Comparator Part 1: Placebo	Participants will receive placebo on Day 1 and followed for 30 days.	Drug: Placebo Oral Capsule
Experimental Part 2: Sequence 1	Participants will receive ABBV-932 on Day 1 in Period 1 under fasting conditions and followed for 30 days. Participants will receive ABBV-932 with food on Day 1 in Period 2 and followed for 30 days.	Drug: ABBV-932 Oral Capsule
Experimental Part 2: Sequence 2	Participants will receive ABBV-932 with food on Day 1 in Period 1 and followed for 30 days. Participants will receive ABBV-932 on Day 1 in Period 2 under fasting conditions and followed for 30 days.	Drug: ABBV-932 Oral Capsule
Experimental Part 3: Japanese Participants: ABBV-932	Japanese participants will receive ABBV-932 on Day 1 in Period 1 and followed for 30 days.	Drug: ABBV-932 Oral Capsule
Placebo Comparator Part 3: Japanese Participants: Placebo	Japanese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.	Drug: Placebo Oral Capsule
Experimental Part 3: Han-Chinese Participants: ABBV-932	Han-Chinese participants will receive placebo on Day 1 in Period 1 and followed for 30 days.	Drug: ABBV-932 Oral Capsule

Recruiting Locations

More Details

NCT ID: NCT05738850
Status: Completed
Sponsor: AbbVie

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.